Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · New England Journal of Medicine · 21K citations
https://doi.org/10.1056/nejmoa043330
M
Michael Weller
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2.8K
Papers
164.6K
Citations
175
h-index
1094
i10-index
Michael Weller is an academic researcher from Royal College of Surgeons in Ireland. The author has contributed to research in topics: Glioma Diagnosis and Treatment & Brain Metastases and Treatment & Radiomics and Machine Learning in Medical Imaging. The author has an h-index of 175, co-authored 2395 publications.
ORCID: 0000-0002-1748-174XPapers by this author
worksEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
2009 · The Lancet Oncology · 7,668 citations
https://doi.org/10.1016/s1470-2045(09)70025-7
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 · New England Journal of Medicine · 7,163 citations
https://doi.org/10.1056/nejmoa043331
DNA methylation-based classification of central nervous system tumours
2018 · Nature · 3,033 citations
https://doi.org/10.1038/nature26000
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
2017 · JAMA · 2,455 citations
https://doi.org/10.1001/jama.2017.18718
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
2020 · Nature Reviews Clinical Oncology · 1,810 citations
https://doi.org/10.1038/s41571-020-00447-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat